BriaCell Therapeutics Corp. (BCTX)

Market Cap	109.71M
Revenue (ttm)	n/a
Net Income (ttm)	-26.11M
Shares Out	15.52M
EPS (ttm)	-1.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,582
Open	6.83
Previous Close	6.83
Day's Range	6.83 - 7.25
52-Week Range	4.06 - 12.09
Beta	1.38
Analysts	Buy
Price Target	11.16 (+57.85%)
Earnings Date	Mar 21, 2023

About BCTX

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is h...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: BCTX

Analyst Forecast

According to 5 analysts, the average rating for BCTX stock is "Buy." The 12-month stock price forecast is $11.16, which is an increase of 57.85% from the latest price.

Price Target

$11.16

(57.85% upside)

Analyst Consensus: Buy